Title : Preclinical Models for Acquired Resistance to Third-Generation EGFR Inhibitors in NSCLC: Functional Studies and Drug Combinations Used to Overcome Resistance.

Pub. Date : 2022

PMID : 35463360






2 Functional Relationships(s)
Download
Sentence
Compound Name
Protein Name
Organism
1 Third-generation (3rd G) EGFR-TKIs, including osimertinib, offer an effective treatment option for patients with NSCLC resistant 1st and 2nd EGFR-TKIs. osimertinib epidermal growth factor receptor Homo sapiens
2 This review provides an overview of preclinical studies developed to investigate the mechanisms of acquired resistance to 3rd G EGFR-TKIs, including osimertinib and rociletinib, across all lines of therapy. osimertinib epidermal growth factor receptor Homo sapiens